On June 4, DualityBio-B fell 5.04% in regular trading, trading at 190.1 HKD/share, with trading volume of approximately 82.11 million HKD. The decline extends a sharp downturn that has seen the stock fall over 25% from its one-month high.

The sustained weakness is linked to ongoing policy headwinds surrounding the US COINS Act, which may expand its scope to include biotechnology in its prohibited investment categories. The legislation could directly constrain cross-border BD licensing, NewCo structures, and US capital flows into Chinese innovative drug companies — all core channels for ADC-focused firms like DualityBio. Additionally, a circulating Chinese draft proposing export controls on biomedical technologies has compounded market anxiety, creating a dual regulatory squeeze on the sector.

Within the Biotechnology sector, stocks broadly declined. Among peers, AKESO fell 4.09%, 3SBIO fell 3.36%, REMEGEN fell 1.43%, INNOVENT BIO fell 1.17%, while BEIGENE rose 1.94%. The company has conducted continuous share buybacks in recent sessions, repurchasing shares on May 28, May 29, June 2, and June 3, signaling management confidence amid the selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)